NasdaqGS:CRNXPharmaceuticals
Crinetics Progresses Rare Endocrine Pipeline With New Data And Early Sales
Crinetics Pharmaceuticals (NasdaqGS:CRNX) reported positive clinical trial results for its congenital adrenal hyperplasia treatment.
The company also announced positive initial sales for its oral therapy for acromegaly, alongside progress on related regulatory milestones.
These updates highlight recent clinical and commercial developments in Crinetics' rare endocrine disease portfolio.
Crinetics Pharmaceuticals focuses on therapies for rare endocrine conditions, an area where treatment...